Bristol Myers To Buy Karuna Therapeutics For $14 Billion

Bristol Myers to buy Karuna Therapeutics for $14 billion

CNBC Television

Bristol Myers Squibb to buy Karuna Therapeutics for $14 billion in cash

CNBC Television

Bristol Myers acquiring Karuna Therapeutics in $14B deal

Bristol’s $14 Billion Karuna Deal Highlights Race for New Drugs | Bloomberg Businessweek

Bloomberg Podcasts

Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

CNBC Television

Bristol-Myers Buy Medarex For $2.4B - Bloomberg

Bloomberg Originals

The state of pharmaceuticals: Bristol-Myers Squibb's plan to buy RayzeBio

CNBC Television

Bristol-Myers Squibb CEO on $13 billion MyoKardia acquisition: 'potentially revolutionary medicine'

CNBC Television

Bristol Myers Squibb CEO on the latest advances in cancer treatment

CNBC Television

Bristol-Myers Squibb to acquire Mirati in deal worth up to $5.8B

Cobenfy (KarXT): A new miracle drug for schizophrenia?

Lauren Kennedy West

Bristol-Myers to buy Celgene in $74B deal

CNBC Television

We have an accelerated opportunity to renew our portfolio, says Bristol Myers Squibb CEO

CNBC Television

Stocks making the biggest moves before the bell: Nike, Bristol Myers, NetEase, Coinbase,

Bristol-Myers upgraded to Buy at Guggenheim

CNBC Television

Bristol Myers Squibb CEO expects Zeposia to renew company's medicine portfolio

CNBC Television

Bristol Myers CEO on Covid Drug Trials, Acquisitions, Texas Plant

Bloomberg Television

Bristol-Myers Squibb stock moves higher after FDA approval for its psoriasis drug

Bristol Myers Plans to Launch Nine New Drugs, CEO Says

Bloomberg Television

CEO of drugmaker Bristol Myers sees 'real need' for policy reform on prescription pricing

CNBC Television